CompletedNCT02520388
HLD200 for ADHD in Everyday Settings for Children Ages 6 to 12
About this title
Read the official source — NCT02520388Medication studyAges 6–12United States
Understand this study
Who was this study for?
Listed age limits: 6 years to 12 years.
- Listed locations
- Newport Beach and 20 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateAugust 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 163
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT02520388
- Official title
Show the full official title
Ph 3 Multicenter DBRCT Parallel Group Study to Evaluate Safety & Efficacy of Evening-dosed HLD200, a Novel Delayed & Extended Release Formulation (DELEXIS) of MPH HCl, on Post-waking, Early Morning Function in Children Aged 6-12 With ADHD
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Newport Beach · Bradenton · Gainesville
16 more locations
- Jacksonville
- Maitland
- North Miami
- Orange City
- Orlando
- South Miami
- Winter Park
- Owensboro
- Durham
- Oklahoma City
- Memphis
- Houston
- Lubbock
- San Antonio
- Clinton
- Seattle
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Ironshore Pharmaceuticals and Development, Inc.
Did this study involve medication?
Yes. The study involved medication, including HLD200 methylphenidate hydrochloride (MPH) Capsules and Placebo.
Who was this study for?
Listed age limits: 6 years to 12 years.
